Knight Sells Priority Review Voucher to Gilead

Knight Therapeutics Inc., through one of its wholly owned subsidiaries, has announced the sale of its Neglected Tropical Disease Priority Review Voucher (PRV). The PRV was granted to Knight in March of this year with the approval of Impavido (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. 

"We are thrilled to successfully transfer our priority review voucher in expectation that this will encourage others to invest in R&D for neglected tropical diseases for the benefit of humanity” said Jonathan Ross Goodman, Director of Knight.